Payment overview · 2025
General Payments
$507.80
30 reported records · 9 companies
Healthcare provider profile · identity verified
Jessica Hite
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SOUTH BOSTON, VA · NPI 1326747973
Verified facts
What the public records show
CMS Open Payments records show Jessica Hite received $507.80 in general payments during 2025 across 30 reported records.
Novo Nordisk Inc accounted for 41.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $211.22 | 41.6% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.03 | 12.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.04 | 10.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.59 | 10.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.41 | 6.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.89 | 6.7% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $26.37 | 5.2% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $26.31 | 5.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.94 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $507.80 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $140.80 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.42 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $70.42 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.84 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 469 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 110 |
| Losartan Potassium | Losartan Potassium | 366 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 321 | 94 |
| Omeprazole | Omeprazole | 288 | 82 |
| Escitalopram Oxalate | Escitalopram Oxalate | 268 | 64 |
| Metformin Hcl | Metformin Hcl | 260 | 72 |
| Gabapentin | Gabapentin | 257 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 235 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 53 |
| Alprazolam | Alprazolam | 187 | 36 |
| Lisinopril | Lisinopril | 184 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 160 | 35 |
| Simvastatin | Simvastatin | 143 | 35 |
| Atenolol | Atenolol | 121 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 28 |
| Potassium Chloride | Potassium Chloride | 111 | 37 |
| Sertraline Hcl | Sertraline Hcl | 107 | 32 |
| Allopurinol | Allopurinol | 103 | 26 |
| Montelukast Sodium | Montelukast Sodium | 99 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 96 | 27 |
| Temazepam | Temazepam | 94 | 16 |
| Glipizide Er | Glipizide | 93 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 86 | 23 |
| Valsartan | Valsartan | 86 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 23 |
| Meloxicam | Meloxicam | 73 | 17 |
| Trazodone Hcl | Trazodone Hcl | 70 | 21 |
| Bupropion Xl | Bupropion Hcl | 69 | 13 |
| Ezetimibe | Ezetimibe | 68 | 14 |
| Prednisone | Prednisone | 65 | 42 |
| Carvedilol | Carvedilol | 62 | 18 |
| Furosemide | Furosemide | 62 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 19 |
| Glipizide | Glipizide | 56 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 45 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Synthroid | Levothyroxine Sodium | 48 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 12 |
| Spironolactone | Spironolactone | 46 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 18 |
| Celecoxib | Celecoxib | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Glyburide | Glyburide | 42 | suppressed |
| Methimazole | Methimazole | 42 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 14 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 20 |
| Methylprednisolone | Methylprednisolone | 31 | 25 |
| Nystatin | Nystatin | 31 | 13 |
| Meclizine Hcl | Meclizine Hcl | 30 | 18 |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 12 |
| Glimepiride | Glimepiride | 29 | 12 |
| Lorazepam | Lorazepam | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Fluconazole | Fluconazole | 21 | 18 |
| Methocarbamol | Methocarbamol | 21 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 11 |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | 13 |
| Cefuroxime | Cefuroxime Axetil | 15 | 15 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Eliquis | Apixaban | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $507.80 · 30 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, CABENUVA, COMIRNATY, Cologuard Collection Kit, Hillrom - Monarch Airway Clearance System, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error